Clinical Case – A Patient With Steroid-Refractory cGVHD
A panelist discusses how graft-vs-host disease (GVHD) manifests through a complex constellation of symptoms affecting multiple organ systems, including the skin (rash, itching), gastrointestinal tract (diarrhea, nausea, abdominal pain), liver (elevated enzymes, jaundice), and lungs (shortness of breath, cough), with severity assessment typically following established criteria.
Video content above is prompted by the following:
- Please give a high-level overview of GVHD symptoms/presentation and how GVHD is assessed.
- What is your initial approach to therapy, and what immediate or long-term factors do you consider when making your initial treatment decisions?
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
